Roche investor science event from ADA 2009

Roche investor science event from ADA 2009

On the call, Roche discussed new phase II data on its PPAR co-agonist aleglitazar (R1439). Further, Roche provided an overall update on its pipeline and emerging franchise in diabetes and metabolic diseases. The presentation was followed by a Q&A session.

Downloads

Presentation

Recorded webcast as MP3 file

More Information

Invitation